home / stock / mirm / mirm articles
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confide...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical compa...
Wednesday, The FDA approved Mirum Pharmaceuticals Inc’s (NASDAQ:MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline...
Patrick Heron, Board Member at Mirum Pharmaceuticals (NASDAQ:MIRM), reported a large insider buy on September 13, according to a new SEC filing. W...
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their con...
News, Short Squeeze, Breakout and More Instantly...
Mirum Pharmaceuticals Inc. Company Name:
MIRM Stock Symbol:
NYSE Market:
2024-04-16 18:00:02 ET Dae Gon Ha from Stifel Nicolaus issued a price target of $48.00 for MIRM on 2024-04-16 16:20:00. The adjusted price target was set to $48.00. At the time of the announcement, MIRM was trading at $24.01. The overall price target consensus is at $57....
2024-04-16 06:15:04 ET Citigroup analyst issues BUY recommendation for MIRM on April 16, 2024 04:53AM ET. The previous analyst recommendation was Buy. MIRM was trading at $23.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...
2024-04-13 05:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...